To investigate its role in CRC, RAF1 was ablated by CRISPR/cas9 genome editing in four CRC cell lines with different KRAS mutational status, microsatellite (MS) phenotype [24] or consensus molecular subtype (CMS) defined by the CRC Subtyping Consortium [24, 25] (RAF1 knockout, KO; Supplementary Table 1). This evidence concerns the gene KRAS and colorectal carcinoma.